$9.53
-0.15-1.55%
At close: Jun 15, 5:00 PM EST
$9.88
0.353.67%
After Hours: Jun 11, 6:55 AM EST
ImmuCell Corp Stock Guidance
ICCCNASDAQ
ImmuCell (ICCC) last issued guidance on April 8, 2026 for Q1 2026. The company guided revenue in the range of $10.40M - $10.40M for the period.
Compared to prior guidance, ImmuCell lowered its revenue forecast from a prior range of $27.60M - $27.60M.
ImmuCell has issued 21 guidance updates between July 7, 2022 and April 8, 2026. During this period, the company raised its outlook 9 times and lowered it 11 times, providing investors with insight into management's evolving expectations.
Latest Guidance Date
Apr 8, 2026
Guidance Period
Q1 2026
Revenue Guidance Range
$10.40M - $10.40M
ImmuCell Guidance History
Review all historical guidance issued by ImmuCell, including EPS and revenue forecasts across quarterly and annual periods.
Loading calendar...
FAQ
What is the most recent guidance for ImmuCell (ICCC)?
The most recent guidance for ImmuCell (ICCC) was reported on April 8, 2026 for Q1 2026. ImmuCell forecasted revenue between $10.40M and $10.40M for the period.
What revenue range did ImmuCell (ICCC) guide for?
ImmuCell (ICCC) guided revenue in the range of $10.40M to $10.40M for Q1 2026.
Did ImmuCell (ICCC) raise or lower guidance?
ImmuCell (ICCC) lowered its revenue guidance from a prior range of $27.60M - $27.60M to $10.40M - $10.40M for Q1 2026.
When did ImmuCell (ICCC) last issue guidance?
ImmuCell (ICCC) last issued guidance on April 8, 2026 for Q1 2026.
